BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29782602)

  • 1. Perfusion CT and PET with 18F-FDG and 18F-FCh in the complex diagnosis of hepatocellular carcinoma.
    Tulin PE; Dolgushin MB; Odzharova AA; Mikhaylov AI; Medvedeva BM; Shiryaev SV; Dolgushin BI
    Eur J Hybrid Imaging; 2017; 1(1):13. PubMed ID: 29782602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
    Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
    Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT.
    Talbot JN; Gutman F; Fartoux L; Grange JD; Ganne N; Kerrou K; Grahek D; Montravers F; Poupon R; Rosmorduc O
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1285-9. PubMed ID: 16802155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection.
    Fartoux L; Balogova S; Nataf V; Kerrou K; Huchet V; Rosmorduc O; Talbot JN
    Nucl Med Commun; 2012 Jul; 33(7):757-65. PubMed ID: 22504293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of Early Posttreatment PET/CT Evaluation Using FDG or
    Reizine E; Chalaye J; Mule S; Regnault H; Perrin C; Calderaro J; Laurent A; Amaddeo G; Kobeiter H; Tacher V; Itti E; Luciani A
    AJR Am J Roentgenol; 2022 Feb; 218(2):359-369. PubMed ID: 34494448
    [No Abstract]   [Full Text] [Related]  

  • 6. PET/CT with
    Filippi L; Bagni O; Notarianni E; Saltarelli A; Ambrogi C; Schillaci O
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36428565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy.
    Wallace MC; Sek K; Francis RJ; Samuelson S; Ferguson J; Tibballs J; Asad A; Preen DB; MacQuillan G; Garas G; Adams LA; Jeffrey GP
    Dig Dis Sci; 2020 Feb; 65(2):647-657. PubMed ID: 31440998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy.
    Paudyal B; Oriuchi N; Paudyal P; Tsushima Y; Iida Y; Higuchi T; Hanaoka H; Miyakubo M; Takano A; Ishikita T; Endo K
    Oncol Rep; 2007 Dec; 18(6):1469-73. PubMed ID: 17982632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET.
    Yamamoto Y; Nishiyama Y; Kameyama R; Okano K; Kashiwagi H; Deguchi A; Kaji M; Ohkawa M
    J Nucl Med; 2008 Aug; 49(8):1245-8. PubMed ID: 18632827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
    Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of
    Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
    Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.
    Trojan J; Schroeder O; Raedle J; Baum RP; Herrmann G; Jacobi V; Zeuzem S
    Am J Gastroenterol; 1999 Nov; 94(11):3314-9. PubMed ID: 10566736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade.
    Wolfort RM; Papillion PW; Turnage RH; Lillien DL; Ramaswamy MR; Zibari GB
    Int Surg; 2010; 95(1):67-75. PubMed ID: 20480845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Malignant tumor with false negative 18F-FDG PET image].
    Dong MJ; Lin XT; Zhao J; Guan YH; Zuo CT; Chen X; Dai JZ; Jiang BD
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):713-7. PubMed ID: 17274383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose.
    Balogova S; Huchet V; Kerrou K; Nataf V; Gutman F; Antoine M; Ruppert AM; Prignon A; Lavolée A; Montravers F; Mayaud C; Cadranel J; Talbot JN
    Nucl Med Commun; 2010 May; 31(5):389-97. PubMed ID: 20145579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic Liver Disease and the Detection of Hepatocellular Carcinoma by [(18)F]fluorocholine PET/CT.
    Kwee SA; Wong LL; Hernandez BY; Chan OT; Sato MM; Tsai N
    Diagnostics (Basel); 2015; 5(2):189-99. PubMed ID: 26090216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT AS AN ASSESSMENT TOOL OF HEPATOCELLULAR CARCINOMA SECONDARY TO NON-ALCOHOLIC FATTY LIVER DISEASE DEVELOPMENT IN EXPERIMENTAL MODEL.
    Levy CS; Costa FGB; Faria DP; Stefano JT; Cogliati B; Oliveira CP
    Arq Gastroenterol; 2019; 56(1):45-50. PubMed ID: 31141073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study.
    Cassou-Mounat T; Balogova S; Nataf V; Calzada M; Huchet V; Kerrou K; Devaux JY; Mohty M; Talbot JN; Garderet L
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1995-2004. PubMed ID: 27121691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis of Hepatocellular Carcinoma Using C11 Choline PET/CT: Comparison with F18 FDG, ContrastEnhanced MRI and MDCT.
    Chotipanich C; Kunawudhi A; Promteangtrong C; Tungsuppawattanakit P; Sricharunrat T; Wongsa P
    Asian Pac J Cancer Prev; 2016; 17(7):3569-73. PubMed ID: 27510010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of 18F-FDG accumulation and arterial enhancement as biomarkers in the assessment of typing, grading and staging of hepatocellular carcinoma using 18F-FDG-PET/CT with integrated dual-phase CT angiography.
    Ferda J; Ferdová E; Baxa J; Kreuzberg B; Daum O; Třeška V; Skalický T
    Anticancer Res; 2015 Apr; 35(4):2241-6. PubMed ID: 25862885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.